title: Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
abstract: Sparfloxacin and levofloxacin were evaluated against 150 Haemophilus influenzae isolates and 149 Neisseria gonorrhoeae isolates in order to define susceptibility testing parameters. Sparfloxacin-susceptible H. influenzae strains were defined as those for which the MICs were < or = 0.25 microgram/ml and the zones were > or = 30 mm, and N. gonorrhoeae susceptible strains were those for which the MICs were < or = 0.03 microgram/ml and the zones were > or = 39 mm (5-micrograms disks). Levofloxacin-susceptible strains of H. influenzae included those for which the MICs were < or = 0.12 microgram/ml and the zones were > or = 32 mm and N. gonorrhoeae susceptible strains were those for which the MICs were < or = 0.12 microgram/ml and the zones were > or = 37 mm (5-micrograms disks). Criteria for a resistant category cannot yet be defined for either quinolone. In multilaboratory studies with different lots of Haemophilus Test Medium, replicate tests with the standard control strain of H. influenzae (ATCC 49247) were evaluated. For sparfloxacin disk tests, the proposed zone size limits were 33 to 42 mm and broth microdilution MIC limits were 0.004 to 0.016 microgram/ml, whereas for levofloxacin tests, zone size limits were 32 to 41 mm and broth microdilution MIC limits were 0.008 to 0.03 microgram/ml. Other multilaboratory studies evaluated tests with supplemented GC agar and N. gonorrhoeae ATCC 49226; for both drugs, zone size limits were 44 to 52 mm and agar dilution MIC limits were 0.004 to 0.016 microgram/ml.
authors.affiliation: Clinical Microbiology Institute, Tualatin, Oregon 97062.
authors.forename: A L
authors.initials: AL
authors.lastname: Barry
authors.forename: P C
authors.initials: PC
authors.lastname: Fuchs
authors.forename: S D
authors.initials: SD
authors.lastname: Allen
authors.forename: J H
authors.initials: JH
authors.lastname: Jorgensen
authors.forename: F C
authors.initials: FC
authors.lastname: Tenover
authors.forename: P R
authors.initials: PR
authors.lastname: Murray
authors.forename: D J
authors.initials: DJ
authors.lastname: Hardy
authors.forename: C N
authors.initials: CN
authors.lastname: Baker
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects*; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests / Q000592:standards*; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D015242:Ofloxacin / Q000494:pharmacology*; D011786:Quality Control; D015363:Quinolones / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D064704:Levofloxacin; D015242:Ofloxacin; C061363:sparfloxacin